EDITORIAL SYNOPSIS The effect of a whole pancreas preparation (Viokase) has been investigated in 11 patients with pancreatic steatorrhoea and in five patients with steatorrhoea due to other causes. The appearance of the stool, faecal fat, and stool and blood radioactivity after a given dose of I'31 triolein (Raolein) were employed in assessing the response to Viokase therapy. Pancreatic steatorrhoea was considerably improved in the majority of patients, and showed some improvement in the remainder. Viokase appeared to be of limited value in the treatment of post-gastrectomy steatorrhoea, and failed to influence fat absorption in steatorrhoea due to disorder of the small intestine.
Patients with gross pancreatic insufficiency present several problems in management. The staggered onset of chronic alcoholism in a usually inadequate personality, severe and often intractable pancreatic pain leading to drug addiction, and progressive pancreatic insufficiency causing diabetes and steatorrhoea frequently produce a pathetic individual bereft of spouse, job, and self respect. Severe pain is usually the most arresting symptom of advanced pancreatitis but in others diabetes and steatorrhoea constitute the major clinical features of the disease. Indeed steatorrhoea may be the presenting feature in some diabetic subjects with pancreatic insufficiency.
Pancreatic steatorrhoea may be a most distressing condition. The fat content of the stools often exceeds that found in other types of steatorrhoea and frequently results in unusually buoyant and offensive stools. The persistent loss of large amounts of fat and protein in the stool contributes to the profound weight loss sometimes found in patients with chronic pancreatitis. In addition, the buoyancy of the stools may cause difficulty in flushing them from the lavatory pan and this, together with the offensive nature of the stools, may be embarrassing socially. 2 a search for more potent preparations. A stable preparation of activated whole raw pancreas (Viokase3) has recently been shown to be remarkably potent in enhancing the absorption of fat and nitrogen in patients with exocrine insufficiency of the pancreas (Longmire, Jordan, and Briggs, 1956; Jordan and Grossman, 1957; Jordan and Grossman, 1959; Polachek and Williard, 1960) . The administration of Viokase at hourly intervals has been shown to be more effective in reducing faecal fat than when given in three doses with meals (Jordan and Grossman, 1959 (Marks and Tompsett, 1958) procedure for chronic pancreatitis with calcification and diabetes. Pancreatic calcification was present in nine of the 11 patients. Seven of the 11 patients were known to have diabetes, and a further three were found to have diabetes by means of the glucose tolerance test; steatorrhoea unassociated with diabetes was present in only one (case 2), a patient with fibrocystic disease of the pancreas, but glucose tolerance was clearly abnormal. Steatorrhoea was a major clinical feature in eight of the patients, one of whom had not considered his stools particularly abnormal.
The non-pancreatic steatorrhoea group comprised two post-gastrectomy subjects and three patients with malabsorption associated with disease of the small intestine and normal pancreatic function as measured by the pancreatic function test. The glucose tolerance test did not suggest a diabetic or pre-diabetic state in the two post-gastrectomy subjects. Steatorrhoea was a major feature in all five patients.
In most cases studies consisted of two five-day experimental periods. No replacement therapy was given during one of the periods, and Viokase, two tablets every hour from 7 a.m. to 9 p.m., was given throughout the other. The majority of the patients received a standard hospital diet containing 75 to 150 g. fat per day.
Fat absorption was measured by both the labelled fat and faecal fat methods in many patients and by only one of these techniques in the remainder. Repeat tests after an interval of about one year were carried out in two patients.
1131 triolein (Raolein) was fed to the fasting patient, and absorption assessed by measuring whole blood radioactivity levels at four and six hours, and by measuring the radioactivity of the stools collected for five days following the administration of Raolein. The patients were not prepared with Lugol's solution (Grossman and Jordan, 1958) . The Raolein was prepared in a special base stable at room temperature to prevent leakage from the gelatin capsule during transit from the United States to South Africa. A peak level of whole blood radioactivity of less than 7 % and of stool radioactivity greater than 7 % was regarded as evidence of abnormal fat absorption.
The fat content of the five-day collection was then measured by the method of van de Kamer, Huinink, and Weijers (1949) after an appropriate interval to allow for decay of stool radioactivity. A stool fat content greater than 7 g. per day indicated abnormal fat absorption.
The effect of Viokase on protein absorption was studied by means of nitrogen balances in the one patient in whom total pancreatectomy had been carried out (case 1). The balances were carried out over two four-day experimental periods. The nitrogen content of the diet was estimated by a dietitian, and aliquots of homogenized four-day stool collections analysed by the Kjeldahl method for faecal nitrogen.
CLINICAL RESULTS PANCREATIC STEATORRHOEA Steatorrhoea was the presenting symptom in five patients, and a major clinical feature in a further two patients (Table I) . Direct questioning elicited a story suggestive of steatorrhoea in the remaining four patients; the steatorrhoea was, in fact, fairly gross in three of these four. The administration of Viokase was associated with a striking improvement in the nature of the stools in eight patients, and was of some value in the remaining three (cases 1, 3, and 9). The improvement was characterized by the stools becoming darker in appearance and less bulky, buoyant, greasy, and offensive in nature. The role of Viokase in improving the general condition of the patient was found difficult to assess because of the pain and diabetes so frequently present in patients with pancreatic steatorrhoea, but a striking gain in weight in two patients (cases 2 and 4) was considered to be due largely to long-term administration of In general, the quantitative measures of fat absorption paralleled the degree of clinical steatorrhoea, but improvement in the character of the stools while the patients were on Viokase therapy was more adequately reflected by stool radioactivity than by stool fat content in some patients (cases 2, 4, and 7).
The results of two four-day nitrogen balance studies carried out in the post-pancreatectomy subject (case 1) before and during Viokase administration is shown in Table IV . Viokase therapy was associated with a slight improvement in nitrogen retention, and the percentage absorption increased from 60.6 to 67A4. Table III . A slight reduction in faecal fat was noted in three patients, one of whom showed a striking improvement in stool radioactivity (case 13) and a good clinical response to Viokase. One of the patients in whom both the appearance and the faecal fat content of the stools remained unaltered showed improved blood radioactivity levels.
DISCUSSION
The results of our study confirms the observations of previous workers regarding the efficacy of pancreatic replacement therapy in improving fat absorption and diminishing the degree of steatorrhoea in patients with pancreatic steatorrhoea (Longmire et al., 1956; Jordan and Grossman, 1957; Jordan and Grossman, 1959; Polachek and Williard, 1960) . There was a marked improvement in the character of the stools in eight of the 11 patients investigated, and in many of these the stools appeared completely normal while they were receiving Viokase. This improvement was reflected by improved fat absorption as measured by faecal fat and stool and plasma radioactivity following a known dose of 1131 triolein (Raolein) and, in the one patient tested, by enhanced nitrogen absorption. Two of the three patients who showed only a moderate clinical response to Viokase had little or no pancreatic function; one had had a total pancreaticoduodenectomy, and the other was a 24-year-old subject with fibrocystic disease of the pancreas with grossly defective pancreatic function as measured by the response to secretin and pancreozymin stimulation. It is conceivable that a larger dose of Viokase may have further improved fat absorption in these two patients. The possibility of associated small bowel disorder could not be excluded in the remaining patient. Most patients agreed that the improvement in the character of the stools more than justified the inconvenience of long-term Viokase therapy. Pancreatic steatorrhoea is not necessarily persistent or progressive, however, and it was found necessary to determine the effect of Viokase withdrawal after a few weeks to determine whether spontaneous improvement had not rendered the replacement therapy redundant. Four of the patients in the present series have found it necessary to remain on Viokase for over 18 months (cases 2, 3, 5, and 10).
The data in patients with post-gastrectomy steatorrhoea suggest that Viokase may have a limited place in the treatment of such patients. Inadequate stimulation of the pancreas following a meal, and impaired mixing of the pancreatic juice with the food due to a transient hold-up of the bile and pancreatic secretion in the afferent loop, have been cited as possible causes of post-gastrectomy steatorrhoea (Shingleton, Isley, Floyd, Sanders, Baylin, Postlethwait, and Ruffin, 1957; Schwartz, Bodansky, and Randall, 1956; Johnson, Horswell, Tyor, Owen, and Ruffin, 1961) and would appear to support the rationale of a therapeutic trial of pancreatic replacement therapy in this condition (Johnson et al., 1961; Rekers, Pack, and Rhoads, 1943; Everson, 1952) .
The difference in response to pancreatic replacement therapy between patients with pancreatic steatorrhoea and small bowel malabsorption has been previously noted and a simple test based on this fact has been advocated in differentiating the two conditions (Polachek and Williard, 1960) . Our experience suggests that the response to Viokase, particularly as measured by changes in blood radioactivity levels, is no more than a useful screening test, and that it cannot be relied upon to replace the more conventional diagnostic tests of pancreatic and small bowel disorder.
